within Pharmacolibrary.Drugs.ATC.B;

model B03XA05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.76,
    Cl             = 0.0205,
    adminDuration  = 600,
    adminMass      = 0.1,
    adminCount     = 1,
    Vd             = 0.0221,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.009833333333333333,
    Tlag           = 10.020000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) used primarily for the treatment of anemia associated with chronic kidney disease (CKD). The drug stimulates endogenous erythropoietin production and improves iron metabolism. Roxadustat is approved for clinical use in several countries including China, Japan, and the European Union, but not the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics parameters in healthy adult volunteers and CKD patients; population: mixed males and females aged 18-75.</p><h4>References</h4><ol><li><p>Czock, D, &amp; Keller, F (2022). Clinical Pharmacokinetics and Pharmacodynamics of Roxadustat. <i>Clinical pharmacokinetics</i> 61(3) 347–362. DOI:<a href=&quot;https://doi.org/10.1007/s40262-021-01095-x&quot;>10.1007/s40262-021-01095-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34905154/&quot;>https://pubmed.ncbi.nlm.nih.gov/34905154</a></p></li><li><p>Groenendaal-van de Meent, D, et al., &amp; den Adel, M (2021). Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor. <i>European journal of drug metabolism and pharmacokinetics</i> 46(1) 141–153. DOI:<a href=&quot;https://doi.org/10.1007/s13318-020-00658-w&quot;>10.1007/s13318-020-00658-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33165773/&quot;>https://pubmed.ncbi.nlm.nih.gov/33165773</a></p></li><li><p>Rekić, D, et al., &amp; Hamrén, B (2021). Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis- and Non-Dialysis-Dependent Patients with Chronic Kidney Disease. <i>Clinical pharmacokinetics</i> 60(6) 759–773. DOI:<a href=&quot;https://doi.org/10.1007/s40262-020-00974-z&quot;>10.1007/s40262-020-00974-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33486718/&quot;>https://pubmed.ncbi.nlm.nih.gov/33486718</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B03XA05;
